menu
    • menu
    [{"orgOrder":0,"company":"HANDOK","sponsor":"AUM Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"CHC2014","moa":"Pan-TRK","graph1":"Oncology","graph2":"Phase I","graph3":"HANDOK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"HANDOK \/ AUM Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"HANDOK \/ AUM Biosciences"},{"orgOrder":0,"company":"HANDOK","sponsor":"AUM Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"CHC2014","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"HANDOK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"HANDOK \/ Handok","highestDevelopmentStatusID":"6","companyTruncated":"HANDOK \/ Handok"},{"orgOrder":0,"company":"HANDOK","sponsor":"Sosei Group Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Clazosentan Sodium","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"HANDOK","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HANDOK \/ Handok","highestDevelopmentStatusID":"12","companyTruncated":"HANDOK \/ Handok"}]

    Find Clinical Drug Pipeline Developments & Deals by HANDOK

    Menu

    HANDOK

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            HANDOK

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            HANDOK

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clazosentan Sodium

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Recipient : Sosei Group Corporation

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Nxera Pharma Announces Exclusive Supply Agreement with Handok for Pivlaz™

                            Details : Handok is responsible for commercialization of Pivlaz (clazosentan sodium), approved in South Korea for preventing cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage.

                            Brand Name : Pivlaz

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 14, 2024

                            Lead Product(s) : Clazosentan Sodium

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : Sosei Group Corporation

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            HANDOK

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            HANDOK

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CHC2014

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : AUM Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AUM Biosciences and HANDOK Presented Phase 1 Data for AUM-601 at ESMO Targeted Anticancer Therapies Congress 2...

                            Details : AUM-601 (CHC2014), a selective second-generation “Pan-TRK” Inhibitor was safe and well-tolerated at dose levels of 50 to 300 mg QD, as recommend Phase 2 dose (RP2D) based on PK profile and safety results.

                            Brand Name : AUM601

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 19, 2022

                            Lead Product(s) : CHC2014

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : AUM Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            HANDOK

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            HANDOK

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CHC2014

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : AUM Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            AUM Biosciences enters in a Strategic Collaboration with Handok and CMG Pharm to develop CHC2014

                            Details : CHC2014 is completing a Phase I in Korea and has shown promising data to justify advancement to a tumor agnostic registrational program. CHC2014 has shown superior in-vivo anti-tumor activity compared to available treatment options.

                            Brand Name : CHC2014

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 11, 2021

                            Lead Product(s) : CHC2014

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : AUM Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth